Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 12, 2011, Pages 1874-1877

  Sharma, Manish ^a   Ravandi, Farhad ^a   Bayraktar, Ulas Darda ^a   Chiattone, Alexandre ^a   Bashir, Qaiser ^a   Giralt, Sergio ^b   Chen, Julianne ^a   Qazilbash, Muzaffar ^a   Kebriaei, Partow ^a   Konopleva, Marina ^a   Andreeff, Michael ^a   Cortes, Jorge ^a   McCue, Deborah ^a   Kantarjian, Hagop ^a   Champlin, Richard E ^a   De Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Sorafenib; Stem cell transplantation

Indexed keywords

AZACITIDINE; CYTARABINE; FLT3 LIGAND; IDARUBICIN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; COMBINED MODALITY THERAPY; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80054771760     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.011     Document Type: Article

References (29)

1. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
2. Hayakawa F., Towatari M., Kiyoi H., et al. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000, 19:624-631.
3. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
4. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
5. Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 2000, 14:675-683.
6. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005, 280:35217-35227.
7. Yu C., Bruzek L.M., Meng X.W., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869.
8. Mori S., Cortes J., Kantarjian H., Zhang W., Andreef M., Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008, 49:2246-2255.
9. Zhang W., Konopleva M., Shi Y.X., et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
10. Borthakur G., Kantarjian H., Ravandi F., et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96:62-68.
11. Safaian N.N., Czibere A., Bruns I., et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009, 33:348-350.
12. Metzelder S., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
13. Choschzick M., Bacher U., Ayuk F., Lebeau A. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation. J Clin Pathol 2010, 63:558-561.
14. Rosinski SL, Deeg HJ, Storb RF, Levis M, Estey EH. Sorafenib in relapse of FLT3-ITD-positive acute myeloid leukemia [e-letter]. Blood. Online 4 May 2010.
15. Sora F., Chiusolo P., Metafuni E., et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. Leuk Res 2011, 35:422-423.
16. Winkler J., Rech D., Kallert S., et al. Sorafenib induces sustained molecular remission in FLT3-ITD-positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report. Leuk Res 2010, 34:e270-e272.
17. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
18. Pratz K.W., Sato T., Murphy K.M., Stine A., Rajkhowa T., Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.
19. Oran B., Giralt S., Couriel D., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007, 21:2540-2544.
20. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
21. Konopleva M., Zhihong Z., Wang R.Y., et al. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen in AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood 2010, 116. Abstract 2358.
22. Yokoyama H., Lundqvist A., Su S., Childs R., et al. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 2010, 116:2858-2859.
23. Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994, 12:1710-1717.
24. Porter D.L., Alyea E.P., Antin J.H., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.
25. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
26. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donorlymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
27. Cluzeau T., de Matteis M., Mounier N., et al. New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. Am J Hematol 2011, 86:619-621.
28. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2010, 116:5420-5431.
29. Agrawal S., Hofmann W.K., Tidow N., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007, 109:3895-3905.